Stock Markets April 13, 2026 06:00 AM

Aena posts stronger March passenger traffic, outpacing capacity growth

Jefferies keeps Buy rating as Spanish airport operator benefits from earlier Easter and prepares for regulatory milestones

By Ajmal Hussain
Aena posts stronger March passenger traffic, outpacing capacity growth

Jefferies' equity research shows Aena's March passenger traffic rose 3.9% year-over-year, surpassing February's 2.8% gain and exceeding capacity growth of 3.1%. Analysts retained a Buy rating, citing upside to returns under the next DORA regulatory cycle and pointing to upcoming catalysts including a CNMC report and first-quarter results.

Key Points

  • March passenger traffic rose 3.9% year-over-year, ahead of February's 2.8% increase and above March capacity growth of 3.1%. - Impacts airports, travel and transportation sectors.
  • Jefferies retained a Buy rating, citing potential upside to return on capital employed through the next DORA regulatory period. - Relevant to infrastructure investors and regulated utilities/asset owners.
  • Upcoming catalysts include the CNMC report on Aena's DORA proposal before summer and Aena's first-quarter results on April 29. - Important for market participants tracking regulatory and earnings developments.

Aena recorded a 3.9% year-over-year increase in passenger traffic in March, according to Jefferies equity research published Monday. That pace marked an acceleration from February, when passenger volumes rose 2.8%, and outstripped the 3.1% expansion in capacity for the month.

Jefferies analysts noted the March result was aided by an earlier Easter holiday this year, which shifted travel patterns and boosted demand. The firm also highlighted that capacity is tracking 5.4% higher year-over-year in April.

The research team - Graham Hunt, Glynis Johnson and Priyal Woolf - left their recommendation on Aena unchanged at Buy. In their view, the company may see upside to expectations for return on capital employed across the next DORA regulatory period, a factor that underpins their maintained stance.

Jefferies' report emphasized Aena's favourable positioning as passenger flows gravitate toward Spain. The analysts trimmed their traffic growth projection for 2026 to 3.0% as part of the update.

Looking ahead, Jefferies identified two near-term catalysts for investors to monitor: the CNMC's report on Aena's DORA proposal, expected before summer, and the company's first-quarter results scheduled for release on April 29. The research note frames these events as potential drivers of fresh information on traffic trends and regulatory outcomes.

This update from Jefferies provides a snapshot of operational momentum and the regulatory context shaping investor expectations. While March's stronger passenger numbers reflect a positive short-term trajectory - in part due to calendar timing - the coming CNMC assessment and the April results are highlighted as the next formal checkpoints for assessing Aena's outlook under evolving regulatory scrutiny.

Risks

  • Regulatory uncertainty tied to the DORA process - the CNMC report and its conclusions could influence expectations around returns and pricing power for the airport operator. - Affects regulated infrastructure and investor sentiment in the sector.
  • Seasonal timing effects - the earlier Easter holiday helped lift March traffic, indicating that calendar shifts can materially affect short-term passenger figures. - Pertinent to travel and airline demand forecasting.
  • Capacity dynamics - with capacity running higher year-over-year (3.1% in March and 5.4% in April), changes in supply could influence load factors and near-term traffic growth comparisons. - Relevant to airport operations and airline capacity planning.

More from Stock Markets

Goldman Shares Slide Despite Strong Q1 Results as Bank Stocks Retreat Apr 13, 2026 BofA Elevates Nokia to Buy, Cites Optical Strength and Hyperscaler AI Demand Apr 13, 2026 Ackman Launches Roadshow for Dual IPOs: Pershing Square Management and New Fund Head to Market Apr 13, 2026 Spyre Therapeutics Shares Rally After SPY001 Meets Phase 2 Primary Endpoint Apr 13, 2026 Citi Research Lowers Rating on ABB, Calling Shares Near Fully Valued Apr 13, 2026